Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666773 | 1.00 | AURKA (0.49) | AURKAAURKBKHKPSMB8JAK3 | |
| SCHEMBL3143344 | 0.88 | AURKA (0.54) | AURKAAURKBJAK3FYNFLT1 | |
| SCHEMBL3146870 | 0.88 | AURKA (0.48) | AURKAAURKBKHKJAK3FYN | |
| SCHEMBL7020607 | 0.85 | LCK (0.59) | JAK3LCKJAK2 | |
| SCHEMBL7022394 | 0.85 | LCK (0.59) | JAK3LCKJAK2 | |
| SCHEMBL3153474 | 0.84 | AURKA (0.49) | AURKAAURKBJAK3FYNFLT1 | |
| SCHEMBL3148016 | 0.84 | AURKA (0.59) | AURKAAURKBJAK3FYNFLT1 | |
| SCHEMBL17627185 | 0.84 | AURKA (0.59) | AURKAAURKBJAK3FYNFLT1 | |
| SCHEMBL7028035 | 0.83 | LCK (0.58) | JAK3LCKJAK2 | |
| SCHEMBL7015949 | 0.83 | LCK (0.58) | JAK3LCKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | claimed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | claimed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | claimed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | claimed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | AURKA 327/4885AURKB 349/4885KHK 337/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | AURKA 440/4885AURKB 448/4885KHK 191/4885 |
| US-20050004140-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | AURKA 327/4885AURKB 349/4885KHK 337/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | AURKA 358/4885AURKB 352/4885KHK 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.